Patents Assigned to GRÜNENTHAL GMBH
  • Publication number: 20160175256
    Abstract: The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with potential for abuse (A), at least one synthetic or natural polymer (C), optionally delayed-release matrix auxiliary substances, physiologically acceptable auxiliary substances (B), optionally a wax (D) and optionally at least one delayed-release coating, component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.
    Type: Application
    Filed: March 1, 2016
    Publication date: June 23, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: JOHANNES BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
  • Publication number: 20160166517
    Abstract: The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.
    Type: Application
    Filed: February 26, 2016
    Publication date: June 16, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: ELISABETH ARKENAU-MARIC, JOHANNES BARTHOLOMÄUS, HEINRICH KUGELMANN
  • Publication number: 20160152624
    Abstract: Novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
    Type: Application
    Filed: February 9, 2016
    Publication date: June 2, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: Florian JAKOB, Ingo KONETZKI, Tobias CRAAN, Antonio NARDI, Christian HESSLINGER
  • Patent number: 9345689
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is an anticonvulsant selected from the group consisting of retigabin, lamotrigine, lacosamide, levetiracetam, carbamazepine, sultiame, phenacemide, felbamate, topiramate, pheneturide, brivaracetam, selectracetam, zonisamide, stiripentol, beclamide, mexiletin, ralfinamide, methylphenobarbital, phenobarbital, primidone, barbexaclone, metharbital, ethotoin, phenyloin, amino(diphenylhydantoin) valeric acid, mephenyloin, fosphenyloin, paramethadione, trimethadione, ethadione, ethosuximide, phensuximide, mesuximide, clonazepam, lorazepam, diazepam, clobazam, oxcarbazepine, eslicarbazepine, rufinamide, valproic acid, valpromide, aminobutyric acid, progabide, tiagabine, and the physiolo
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: May 24, 2016
    Assignee: Gruenenthal GmbH
    Inventors: Stefanie Frosch, Klaus Linz, Thomas Christoph
  • Patent number: 9339816
    Abstract: The present invention relates to a reactor array for producing and/or analyzing products, comprising a plurality of vessels in which products can be produced on a preparative or analytical scale.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: May 17, 2016
    Assignee: Grünenthal GmbH
    Inventors: Michael Gruss, Matthias Ridder
  • Publication number: 20160120810
    Abstract: The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed.
    Type: Application
    Filed: January 13, 2016
    Publication date: May 5, 2016
    Applicant: Grünenthal GmbH
    Inventors: Judy Ashworth, Elisabeth Arkenau-Maric, Johannes Bartholomäus, Heinrich Kugelmann
  • Patent number: 9320729
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is a propionic acid derivative selected from the group consisting of ibuprofen, naproxen, ketoprofen, flurbiprofen, fenoprofen, fenbufen, suprofen, pirprofen, indoprofen, tiaprofenic acid, oxaprozin, ibuproxam, flunoxaprofen, alminoprofen, naproxcinod, and the physiologically acceptable salts thereof.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: April 26, 2016
    Assignee: Gruenenthal GmbH
    Inventors: Stefanie Frosch, Klaus Linz, Klaus Schiene
  • Patent number: 9320725
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from gabapentinoids and the physiologically acceptable salts thereof.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: April 26, 2016
    Assignee: Gruenenthal GmbH
    Inventors: Stefanie Frosch, Klaus Linz, Thomas Christoph
  • Patent number: 9315490
    Abstract: The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: April 19, 2016
    Assignee: GRUENENTHAL GMBH
    Inventors: Ingo Konetzki, Tobias Craan, Florian Jakob, Antonio Nardi, Christian Hesslinger, Andre Welbers
  • Publication number: 20160101022
    Abstract: The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of ?500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force.
    Type: Application
    Filed: November 25, 2015
    Publication date: April 14, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: Elisabeth ARKENAU-MARIC, Johannes BARTHOLOMÄUS, Heinrich KUGELMANN
  • Patent number: 9308196
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: April 12, 2016
    Assignee: Gruenenthal GmbH
    Inventors: Stefanie Frosch, Klaus Linz, Klaus Schiene
  • Patent number: 9302988
    Abstract: The invention relates to pyrrole carboxamides bearing a fluoromethyl-moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: April 5, 2016
    Assignee: GRÜNENTHAL GMBH
    Inventors: Stefan Schunk, Melanie Reich, Henning Steinhagen, Nils Damann, Michael Haurand, Achim Kless, Philip Skone, Richard Hamlyn, Robert Kirby, Marc Rogers, Kathy Sutton
  • Patent number: 9296749
    Abstract: The present invention relates to crystalline forms of cis-(E)-4-(3-Fluorophenyl)-2?,3?,4?,9?-tetrahydro-N,N-dimethyl-2?-(1-oxo-3-phenyl-2-propenyl)-spiro[cyclohexane-1,1?[1H]-pyrido[3,4-b]indol]-4-amine, pharmaceutical compositions and medicaments comprising these modifications, the use of these modifications as well as to a process for making the crystalline forms.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 29, 2016
    Assignee: Gruenenthal GmbH
    Inventor: Michael Gruss
  • Patent number: 9289416
    Abstract: A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6?-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: March 22, 2016
    Assignee: Gruenenthal GmbH
    Inventors: Nadja Gruening, Marc Schiller, Ashish Hemani, Chris Kirby, Ingo Friedrich, John Bothmer, Andreas Scholz
  • Publication number: 20160074388
    Abstract: The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.
    Type: Application
    Filed: November 19, 2015
    Publication date: March 17, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU MARIC
  • Patent number: 9284286
    Abstract: The invention relates to specific carboxamides, to processes for their preparation, to medicaments comprising these compounds and to the use of these compounds in the preparation of medicaments.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: March 15, 2016
    Assignee: GRÜNENTHAL GMBH
    Inventors: Simon Lucas, Sven Kühnert, Gregor Bahrenberg, Wolfgang Schröder
  • Patent number: 9278103
    Abstract: Substituted 6-amino-nicotinamides, pharmaceutical compositions containing these compounds and also use of these compounds in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: March 8, 2016
    Assignee: GRÜNENTHAL GMBH
    Inventors: Sven Kühnert, Gregor Bahrenberg, Achim Kless, Wolfgang Schröder, Simon Lucas
  • Publication number: 20160058710
    Abstract: The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of ?500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force.
    Type: Application
    Filed: November 9, 2015
    Publication date: March 3, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: Elisabeth ARKENAU MARIC, Johannes BARTHOLOMÄUS, Heinrich KUGELMANN
  • Publication number: 20160031857
    Abstract: The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
    Type: Application
    Filed: October 15, 2015
    Publication date: February 4, 2016
    Applicant: GRÜNENTHAL GMBH
    Inventors: Ingo KONETZKI, Florian JAKOB, Tobias CRAAN, Christian HESSLINGER, Paul RATCLIFFE, Antonio NARDI
  • Patent number: 9248122
    Abstract: The invention relates to substituted heteroquinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: February 2, 2016
    Assignee: GRÜNENTHAL GMBH
    Inventors: Sven Kühnert, Simon Lucas, Gregor Bahrenberg, Wolfgang Schröder